Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chronic obstructive ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback